Cytostatic therapy and blood antioxidants/prooxidants balance in acute myeloblastic leukemia patients

• Authors: Daniela Gerova , Vladimir Gerov , Tatyana Yankova , Liana Gercheva , Diana Ivanova
• Languages of publication: EN

Abstracts

EN

To analyze the effects of conventional polychemotherapy of acute myeloblastic leukemia (AML) patients on the prooxidants/antioxidants balance in plasma total antioxidant status (TAS) and a single plasma antioxidant - uric acid (UA) were measured. Lipid peroxidation was assessed by malonedialdehyde (MDA) content. Total serum iron was monitored as a potential source of nontransferrin-bound iron with a role in initiation of oxidative burst. A group of patients in the acute phase of AML (group A) and a group of patients in complete remission of AML (group B) were studied. A strong correlation between UA values and TAS (r = 0.8 for group A, r = 0.9 for group B) was revealed in the course of the treatment. Strong negative correlation (r = −0.9) between TAS and MDA was shown for both groups. Total iron significantly increased in the course of chemotherapy. We have established that polychemotherapy leads to the consumption of antioxidants and increased lipid peroxidation in AML patients. An appropriate supplementation with antioxidants at the end of the polychemotherapy treatment could be considered.

Keywords

EN

Acute myeloblastic leukemia; total antioxidant status; uric acid; lipid peroxidation; total serum iron

• Publisher: De Gruyter Open
• Journal: Open Medicine
• Year: 2006
• Volume: 1
• Issue: 1
• Pages: 35-45

Dates

published

1 - 3 - 2006

online

1 - 3 - 2006

Contributors

author

Daniela Gerova

• Department of Preclinical, Clinical Pharmacology and Biochemistry, University of Medicine, Varna, Bulgaria

author

Vladimir Gerov

• Department of Internal Medicine, Clinics of Hematology, University of Medicine, Varna, Bulgaria

author

Tatyana Yankova

• Department of Preclinical, Clinical Pharmacology and Biochemistry, University of Medicine, Varna, Bulgaria

author

Liana Gercheva

• Department of Internal Medicine, Clinics of Hematology, University of Medicine, Varna, Bulgaria

author

Diana Ivanova

• Department of Preclinical, Clinical Pharmacology and Biochemistry, University of Medicine, Varna, Bulgaria

References

• [1] R.A. Floyd: “Role of oxygen free radicals in carcinogenesis and brain ischemia”, FASEB J., Vol. 4, (1990), pp. 2587–2597.
• [2] G.S. Devi, M.H. Prasad, I. Saraswathi, D. Raghu, D.N. Rao and P.P. Reddy: “Free radicals antioxidant enzymes and lipid peroxidation in different types of leukemias”, Clin. Chim. Acta, Vol. 293, (2000), pp. 53–62. http://dx.doi.org/10.1016/S0009-8981(99)00222-3[Crossref]
• [3] A.F. Abdel-Aziz and M.M. El-Nggar: “Superoxide dismutase activities in serum and white blood cells of patients with some malignancies”, Cancer Lett., Vol. 113, (1997), pp. 61–64. http://dx.doi.org/10.1016/S0304-3835(96)04590-9[Crossref]
• [4] M.P. Look and E. Musch: “Lipid peroxides in the polychemotherapy of cancer patients”, Chemother., Vol. 40, (1994), pp. 8–15. http://dx.doi.org/10.1159/000239163[Crossref]
• [5] M. Durken, C. Herrnring, B. Finckh, S. Nagel, P. Nielsen, R. Fischer, H.M. Berger, R.M. Moison, U. Pichlmeier, B. Kohlschutter, A.R. Zander and A. Kohlschutter: “Impaired plasma antioxidative defense and increased nontransferrin-bound iron during high-dose chemotherapy and radiochemotherapy preceding bone marrow transplantation”, Free Rad. Biol. Med., Vol. 28, (2000), pp. 887–894. http://dx.doi.org/10.1016/S0891-5849(00)00174-X[Crossref]
• [6] A. Gonenc, Y. Ozkan, M. Torun and B. Simsek: “Plasma malonedialdahyde (MDA) levels in breast and lung cancer patients”, J. Clin. Pharm. Ther., Vol. 26, (2001), pp. 141–144. http://dx.doi.org/10.1046/j.1365-2710.2001.00334.x[Crossref]
• [7] G.O. Monteiro, N.G. Oliveira, A.S. Rodrigues, A. Laires, T.C. Ferreira, E. Limbert, A. Leonard, G. Gerber and J. Rueff: “Cytogenetic alterations and oxidative stress in thyroid cancer patients after iodine-131 therapy”, Mutagenesis, Vol. 15, (2000), pp. 69–75. http://dx.doi.org/10.1093/mutage/15.1.69[Crossref]
• [8] R. Kumaraguruparan, R. Subapriya, P. Viswanathan and S. Nagini: “Tissue lipid peroxidation and antioxidant status in patients with adenocarcinoma of the breast”, Clin. Chim. Acta, Vol. 325, (2002), pp. 165–170. http://dx.doi.org/10.1016/S0009-8981(02)00292-9[Crossref]
• [9] J.A. Hickman: “Apoptosis induced by anticancer drugs”, Cancer Metastasis Rev., Vol. 11, (1992), pp. 121–139. http://dx.doi.org/10.1007/BF00048059[Crossref]
• [10] S. Ĺmily, J.A. Williams, R.M. Hinson, S. Senturker and Y. Lee: “Oxidative stress interferes with cancer chemotherapy: inhibition of lymphoma cell apoptosis and phagocytosis”, Blood, Vol. 96, (2000), pp. 307–313.
• [11] S.F. Llesuy, J. Milei, B.S. Gonzalez, A. Boveris: “Myocardial damage induced by doxorubicins: hydroperoxide-initiated chemiluminescence and morphology”, Free Rad. Biol. Med., Vol. 8, (1990), pp. 259–264. http://dx.doi.org/10.1016/0891-5849(90)90071-P[Crossref]
• [12] M. Erhola, P. Kellokumpu-Lehtinen, T. Metsa-Ketela, K. Alanko and M.M. Nieminen: “Effects of anthracyclin-based chemotherapy on total plasma antioxidant capacity in small cell lung cancer patients”, Free Rad. Biol. Med., Vol. 21, (1996), pp. 383–390. http://dx.doi.org/10.1016/0891-5849(96)00041-X[Crossref]
• [13] T. Siitonen, P. Alaruikka, P. Mantymaa, E.R. Savolainen, T.J. Kavanagh, C.M. Krejsa, C.C. Franklin, V. Kinnula and P. Koistinen: “Protection of acute myeloblastic leukemia cells against apoptotic cell death by high glutathione and gamma-glutamylcysteine synthetase levels during etoposide-induced oxidative stress”, Ann. Oncol., Vol. 10, (1999), pp. 1361–1367. http://dx.doi.org/10.1023/A:1008382912096[Crossref]
• [14] J.P. Fabisiak, V.B. Ritov and V.E. Kagan: “Reversible thiol-dependent activation of ryanodine-sensitive Ca2+ release channel by etoposide phenoxyl radical”, Antioxid. Redox Signal, Vol. 2, (2000), pp. 73–82. http://dx.doi.org/10.1089/ars.2000.2.1-73[Crossref]
• [15] N.A. Pham and D.W. Hedley: “Respiratory chain-generated oxidative stress following treatment of leukemic blasts with DNA-damaging agents”, Exp. Cell Res., Vol. 264, (2001), pp. 345–348. http://dx.doi.org/10.1006/excr.2000.5148[Crossref]
• [16] K.L. Backway, E.A. McCulloch, S. Chow, D.W. Hedley: “Relationships between the mitochondrial permeability transition and oxidative stress during ara-C toxicity”, Cancer Res., Vol. 57, (1997), pp. 2446–2454.
• [17] D.W. Hedley and E.A. McCulloch: “Generation of reactive oxygen intermediates after treatment of blasts of acute myeloblastic leukemia with cytosine arabinoside: role of bcl-2”, Leukemia, Vol. 10, (1996), pp. 1143–1149.
• [18] V.S. Ghalaut, P.S. Ghalaut and S. Singh: “Lipid peroxidation in leukaemia”, J. Assoc. Physicians India, Vol. 47, (1999), pp. 403–405.
• [19] B.F. Becker: “Towards the physiological function of uric acid”, Free Rad. Biol. Med., Vol. 14, (1993), pp. 615–631. http://dx.doi.org/10.1016/0891-5849(93)90143-I[Crossref]
• [20] N.A. Porter, J. Nixon and R. Isaac: “Cyclic peroxides and the thiobarbituric assay”, Biochim. Biophys. Acta, Vol. 441, (1976), pp. 506–512.
• [21] N.J. Miller, C. Rice-Evans, M.J. Davies, V. Gopinathan and A. Milner: “A novel method for measuring antioxidant capacity and its application to monitoring the antioxidant status in premature neonates”, Clin. Sci., Vol. 84, (1993), pp. 407–412.
• [22] H. Ihara, N. Hashizume, T. Hasegawa and M. Yoshida: “Antioxidant capacities of ascorbic acid, uric acid, alpha-tocopherol, and bilirubin can be measured in the presence of another antioxidant, serum albumin”, J. Clin. Lab. Anal., Vol. 18, (2004), pp. 45–49. http://dx.doi.org/10.1002/jcla.20002[Crossref]

Identifiers

DOI

10.2478/s11536-006-0009-8